The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.

1 report, 1 independent Updated Jun 30

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Kyowa Kirin

Keep exploring

Part of

FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement. All 1 developments

The entities involved

FDA
- FDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.11:05
- An industrial event related to a manufacturing crisis is triggering regulatory clocks overseen by the FDA.07:39
Kyowa Kirin
pharmaceutical company
- Kyowa Kirin's collaboration agreement is driving revenue, with executives Edward Wilson and Leoni involved in the partnership.06:50

Related events

Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.Nov 2
FDA approval is the goal for product candidates from Daré Bioscience, Inc.Jun 7

Coverage

Newest first; wire copies grouped

Jun 30daily-tribune.com